Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Public ClinicalTrials.gov record NCT05741476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 μg in 4-7-year-old Children With Peanut Allergy (VITESSE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Study identification
- NCT ID
- NCT05741476
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Years to 7 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2023 (Actual)
- Primary completion
- Nov 6, 2025 (Actual)
- Completion
- Oct 2029 (Estimated)
- Last update posted
- Jan 22, 2026
2023 – 2029
United States locations
- U.S. sites
- 50
- U.S. states
- 24
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| DBV Investigative Site | Birmingham | Alabama | 35233 | — |
| DBV Investigative Site | Tucson | Arizona | 85724 | — |
| DBV Investigative Site | Little Rock | Arkansas | 72202 | — |
| DBV Investigative Site | Los Angeles | California | 90027 | — |
| DBV Investigative Site | Los Angeles | California | 90095 | — |
| DBV Investigative site | Mission Viejo | California | 92691 | — |
| DBV Investigative Site | San Diego | California | 92123 | — |
| DBV Investigative Site | San Francisco | California | 94158 | — |
| DBV Investigative Site | San Jose | California | 95117 | — |
| DBV Investigative Site | Aurora | Colorado | 80045 | — |
| DBV Investigative Site | Colorado Springs | Colorado | 80907 | — |
| DBV Investigative Site | Washington D.C. | District of Columbia | 20010 | — |
| DBV Investigative Site | Hollywood | Florida | 33021 | — |
| DBV Investigative Site | Miami | Florida | 33136 | — |
| DBV Investigative Site | St. Petersburg | Florida | 33701 | — |
| DBV Investigative Site | Tampa | Florida | 33613 | — |
| DBV Investigative site | Atlanta | Georgia | 30329 | — |
| DBV Investigative Site | Marietta | Georgia | 30060 | — |
| DBV Investigative Site | Chicago | Illinois | 60611 | — |
| DBV Investigative Site | Normal | Illinois | 61761 | — |
| DBV Investigative Site | Indianapolis | Indiana | 46202 | — |
| DBV Investigative Site | Louisville | Kentucky | 40215 | — |
| DBV Investigative Site | Baltimore | Maryland | 21287 | — |
| DBV Investigative Site | Chevy Chase | Maryland | 20815 | — |
| DBV Investigative Site | Boston | Massachusetts | 02114 | — |
| DBV Investigative Site | Boston | Massachusetts | 02115 | — |
| DBV Investigative Site | Taunton | Massachusetts | 02780 | — |
| DBV Investigative Site | Ann Arbor | Michigan | 48106 | — |
| DBV Investigative Site | Ypsilanti | Michigan | 48197 | — |
| DBV Investigative Site | Maplewood | Minnesota | 55109 | — |
| DBV Investigative Site | Kansas City | Missouri | 64108 | — |
| DBV Investigative Site | Great Neck | New York | 11021 | — |
| DBV Investigative Site | New York | New York | 10016 | — |
| DBV Investigative Site | New York | New York | 10029 | — |
| DBV Investigative Site | Rochester | New York | 14642 | — |
| DBV Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| DBV Investigative Site | Cincinnati | Ohio | 45229 | — |
| DBV Investigative Site | Cleveland | Ohio | 44106 | — |
| DBV Investigative Site | Cleveland | Ohio | 44195 | — |
| DBV Investigative Site | Columbus | Ohio | 43205 | — |
| DBV Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| DBV Investigative Site | Pittsburgh | Pennsylvania | 15224 | — |
| DBV Investigative Site | Memphis | Tennessee | 38105 | — |
| DBV Investigative Site | Nashville | Tennessee | 37232 | — |
| DBV Investigative Site | Austin | Texas | 78723 | — |
| DBV Investigative Site | Dallas | Texas | 75235 | — |
| DBV Investigative Site | Houston | Texas | 77030 | — |
| DBV Investigative Site | Seattle | Washington | 98101 | — |
| DBV Investigative Site | Seattle | Washington | 98115 | — |
| DBV Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05741476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05741476 live on ClinicalTrials.gov.